Anraku T - Search Results

1

Development of patient‑derived tumor organoids and a drug testing model for renal cell carcinoma.

Kazama A, Anraku T, Kuroki H, Shirono Y, Murata M, Bilim V, Ugolkov A, Saito K, Tomita Y. Kazama A, et al. Among authors: anraku t. Oncol Rep. 2021 Oct;46(4):226. doi: 10.3892/or.2021.8177. Epub 2021 Sep 1. Oncol Rep. 2021. PMID: 34468011 Free PMC article.

2

Case of Large Cecoureterocele with Contralateral Renal Rupture in Neonate.

Obara K, Anraku T, Ikeda M, Komatsu S, Mizusawa T, Maruyama R, Tomita Y. Obara K, et al. Among authors: anraku t. Urol Int. 2016;97(2):238-40. doi: 10.1159/000445525. Epub 2016 Apr 6. Urol Int. 2016. PMID: 27045294

3

Retrospective Analysis to Determine the Optimal Timing to Discontinue Continuous Antibiotic Prophylaxis in Patients with Primary Vesicoureteral Reflux.

Anraku T, Obara K, Tasaki M, Tomita Y. Anraku T, et al. Urol Int. 2019;102(4):462-467. doi: 10.1159/000497312. Epub 2019 Mar 27. Urol Int. 2019. PMID: 30917379

4

[THE USE OF BORTEZOMIB FOR THE TREATMENT OF CHRONIC ANTIBODY MEDIATED REJECTION AFTER KIDNEY TRANSPLANTATION].

Tasaki M, Saito K, Nakagawa Y, Nobushita T, Anraku T, Kuroki H, Imai N, Ito Y, Tomita Y. Tasaki M, et al. Among authors: anraku t. Nihon Hinyokika Gakkai Zasshi. 2018;109(2):68-73. doi: 10.5980/jpnjurol.109.68. Nihon Hinyokika Gakkai Zasshi. 2018. PMID: 31006744 Free article. Japanese.

5

Free Tube Graft Urethroplasty for Repair of Hypospadias.

Obara K, Hoshii T, Hoshino S, Yamana K, Anraku T, Maruyama R, Kuroki H, Ishizaki F, Yamazaki H, Tomita Y. Obara K, et al. Among authors: anraku t. Urol Int. 2020;104(5-6):386-390. doi: 10.1159/000504146. Epub 2019 Dec 4. Urol Int. 2020. PMID: 31801150

6

9-ING-41, a small molecule inhibitor of GSK-3beta, potentiates the effects of anticancer therapeutics in bladder cancer.

Kuroki H, Anraku T, Kazama A, Bilim V, Tasaki M, Schmitt D, Mazar AP, Giles FJ, Ugolkov A, Tomita Y. Kuroki H, et al. Among authors: anraku t. Sci Rep. 2019 Dec 27;9(1):19977. doi: 10.1038/s41598-019-56461-4. Sci Rep. 2019. PMID: 31882719 Free PMC article.

7

Clinically relevant GSK‑3β inhibitor 9‑ING‑41 is active as a single agent and in combination with other antitumor therapies in human renal cancer.

Anraku T, Kuroki H, Kazama A, Bilim V, Tasaki M, Schmitt D, Mazar A, Giles FJ, Ugolkov A, Tomita Y. Anraku T, et al. Int J Mol Med. 2020 Feb;45(2):315-323. doi: 10.3892/ijmm.2019.4427. Epub 2019 Dec 12. Int J Mol Med. 2020. PMID: 31894292 Free PMC article.

8

Histone deacetylase 6 inhibition in urothelial cancer as a potential new strategy for cancer treatment.

Kuroki H, Anraku T, Kazama A, Shirono Y, Bilim V, Tomita Y. Kuroki H, et al. Among authors: anraku t. Oncol Lett. 2021 Jan;21(1):64. doi: 10.3892/ol.2020.12315. Epub 2020 Nov 20. Oncol Lett. 2021. PMID: 33281975 Free PMC article.

9

Tumor-infiltrating immune cell status predicts successful response to immune checkpoint inhibitors in renal cell carcinoma.

Kazama A, Bilim V, Tasaki M, Anraku T, Kuroki H, Shirono Y, Murata M, Hiruma K, Tomita Y. Kazama A, et al. Among authors: anraku t. Sci Rep. 2022 Nov 27;12(1):20386. doi: 10.1038/s41598-022-24437-6. Sci Rep. 2022. PMID: 36437290 Free PMC article.

10

Targeting Pro-Survival Autophagy Enhanced GSK-3β Inhibition-Induced Apoptosis and Retarded Proliferation in Bladder Cancer Cells.

Shirono Y, Bilim V, Anraku T, Kuroki H, Kazama A, Murata M, Hiruma K, Tomita Y. Shirono Y, et al. Among authors: anraku t. Curr Oncol. 2023 May 28;30(6):5350-5365. doi: 10.3390/curroncol30060406. Curr Oncol. 2023. PMID: 37366889 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

41 results

Search Page

Filters